A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors
- 146 Downloads
To determine the maximal tolerated doses (MTD) and dose-limiting toxicities (DLT) of combination of 24-h infusions of gemcitabine and irinotecan in patients with advanced solid tumors.
Patients and methods
Twenty-four patients with advanced solid tumors received gemcitabine as a 24-h IV infusion followed by a 24-h infusion of irinotecan every 2 weeks. Pharmacokinetic parameters of both drugs and their metabolites were estimated by using non-compartmental methods.
Twenty-four patients were fully evaluable for toxicity. DLT was observed in two of six patients at irinotecan/gemcitabine 110/150 mg/m2 (grade 3 diarrhea and grade 3 GI bleeding). No patient developed acute cholinergic symptoms at any dose. Other toxicities were ≤grade 2 nausea, vomiting, and fatigue. Tumor responses were observed in three patients (one CR: cholangiocarcinoma; two PR: SCLC, gastric neuroendocrine tumor). Stable disease >3 months was found in six patients including five patients who had failed short infusions of either drug. Pharmacokinetic analysis showed that C max of each drug and active metabolites were dose-dependent. High dose of gemcitabine increased C max, AUC, and T1/2 of irinotecan. However, gemcitabine had minimal effects on SN-38.
The recommended dose for Phase II studies is gemcitabine 125 mg/m2 given as a 24-h IV infusion on D1 and D15, followed by a 24-h IV infusion of irinotecan 110 mg/m2 on D2 and D16. Both pretreated patients and chemo-naive patients seem to tolerate higher doses of this combination without significant toxicities. Objective responses among patients with solid tumors, in particular cholangiocarcinoma and small cell lung cancer merits further investigation.
KeywordsGemcitabine Irinotecan Colon cancer Cholangiocarcinoma Gastrointestinal bleeding SN-38 Fixed dose rate infusion Pancreatic cancer Small cell lung cancer
- 2.Takimoto CH, Arbuck SA (1996) Camptothecin analogs. In: Chabner BA, Longo DL (eds) Cancer chemotherapy & biotherapy. Principles & practice. Lippincott-Raven Publishers, PhiladelphiaGoogle Scholar
- 8.Ruiz van Halperen VWT, Veerman G, Vermorken JB, Peters GJ (1994) Improved antitumor effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in murine colon carcinomas, when administered as continuous infusions. Proc Am Assoc Cancer Res 35:447Google Scholar
- 13.Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402–3408PubMedCrossRefGoogle Scholar
- 18.Slatter JG, Su P, Sams JP et al (1998) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessement of potential drug interactions. Drug Metab Dispos 25:1157–1164Google Scholar
- 20.Yamazaki H, Funakoshi S, Hirano A et al. (1999) Phase I & pharmacokinetic study of irinotecan (CPT-11) given by 24 hours infusion plus oral uracil/tegafur (UFT) in patients with lung cancer. Proc Am Soc Clin Oncol 18: abstr 2036Google Scholar
- 29.Piantadosi S (1997) Clinical trials: a methodologic perspective. Wiley, New York, pp 151–155Google Scholar
- 35.Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMedGoogle Scholar
- 36.Stewart DF, Ma M, Furman WL et al (1998) Pharmocokinetics of inrinotecan and its active metabolite SN-38 in children with recurrent solid tumors after protracted low dose IV irinotecan. Proc Am Soc Clin Oncol 17:186aGoogle Scholar
- 37.Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS (2000) Pharmacokinetics, metabolism and excretion of irinotecan (CPT-11) following I.V. infusion of [14C] CPT-11 in cancer patients. Drug Metab Dispos 28:423–433PubMedGoogle Scholar